Nataliya A. Tsvetkova
Research Subjects
Research Interests
Nataliya A. Tsvetkova has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Elena Vasilevna Volchkova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
3 shared publications - Marina Viktorovna Bazarova
Moscow City Health Department
3 shared publications - Svetlana V. Smetanina
City Clinical Hospital named after V.P. Demikhov
3 shared publications - Aleksandra G. Rosatkevich
National Research Centre of Epidemiology and Microbiology
2 shared publications - Andrey Nikolaevich Gerasimov
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency
2 shared publications - Anna D. Panova
The N.F. Gamaleya Research Center of Epidemiology and Microbiology of Ministry of Health 123098 Moscow Russia
2 shared publications
Latest Publications
- 1 January 2026
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 15 (1)
Kidney pathology in HIV-Positive patients according to autopsy data
- 1 January 2026
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 15 (1)
Kidney pathology in HIV-Positive patients according to autopsy data
- Open Access
- 14 December 2025
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 30 (3) , 180-193
Predictors of severe COVID-19: older age and comorbidity
BACKGROUND: Older age and comorbidity are recognized as significant risk factors for severe COVID-19. However, the combined impact of these factors on disease outcomes, especially in different age groups, remains unclear. This study focuses on older patients with chronic comorbidities in order to address this gap. AIM: This study aimed to evaluate the role of older age and comorbidities in prediction of severe COVID-19 and mortality in hospitalized patients. METHODS: This cross-sectional, retrospective study included 604 patients aged 18–99 years who were treated at Infectious Diseases Clinical Hospital No. 2 of the Moscow Healthcare Department for laboratory-confirmed (ICD-10 code: U07.1) COVID-19 between September 2020 and November 2022. Demographic characteristics, comorbidities, clinical outcomes (recovery, improvement, and mortality rates), and COVID-19 severity were evaluated. RESULTS: An analysis of 604 hospitalized patients revealed an increase in mortality rates with age: 4.1% in patients under 60 years old, 12.7% in patients aged 60–74 years, 16.4% in patients aged 75–89 years, and 21.9% in patients aged 90 years and older. The most common comorbidity-associated risk factors included chronic kidney disease (mortality rate: 23.2%), myocardial ischemia (19.7%), and type 2 diabetes mellitus (18%). The infection was atypical, without fever in 21% of patients, primarily those in the older age group. Stratified analysis showed that the role of specific risk factors, such as chemotherapy, myocardial ischemia, and chronic kidney disease, varied across age groups. CONCLUSION: Older age and comorbidities are independent risk factors for severe COVID-19 and fatal outcomes. Patients over the age of 75 years with chronic diseases require special attention. Early diagnosis and personalized management strategies may improve outcomes in this age group.
- 14 December 2025
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 30 (3) , 180-193
Open AccessPredictors of severe COVID-19: older age and comorbidity
BACKGROUND: Older age and comorbidity are recognized as significant risk factors for severe COVID-19. However, the combined impact of these factors on disease outcomes, especially in different age groups, remains unclear. This study focuses on older patients with chronic comorbidities in order to address this gap. AIM: This study aimed to evaluate the role of older age and comorbidities in prediction of severe COVID-19 and mortality in hospitalized patients. METHODS: This cross-sectional, retrospective study included 604 patients aged 18–99 years who were treated at Infectious Diseases Clinical Hospital No. 2 of the Moscow Healthcare Department for laboratory-confirmed (ICD-10 code: U07.1) COVID-19 between September 2020 and November 2022. Demographic characteristics, comorbidities, clinical outcomes (recovery, improvement, and mortality rates), and COVID-19 severity were evaluated. RESULTS: An analysis of 604 hospitalized patients revealed an increase in mortality rates with age: 4.1% in patients under 60 years old, 12.7% in patients aged 60–74 years, 16.4% in patients aged 75–89 years, and 21.9% in patients aged 90 years and older. The most common comorbidity-associated risk factors included chronic kidney disease (mortality rate: 23.2%), myocardial ischemia (19.7%), and type 2 diabetes mellitus (18%). The infection was atypical, without fever in 21% of patients, primarily those in the older age group. Stratified analysis showed that the role of specific risk factors, such as chemotherapy, myocardial ischemia, and chronic kidney disease, varied across age groups. CONCLUSION: Older age and comorbidities are independent risk factors for severe COVID-19 and fatal outcomes. Patients over the age of 75 years with chronic diseases require special attention. Early diagnosis and personalized management strategies may improve outcomes in this age group.
- Open Access
- 1 June 2023
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 28 (2) , 67-77
Epidemic season 2021–2022: Frequency of co-infection by respiratory viral pathogens
BACKGROUND: This study was conducted to determine the characteristics of various viral respiratory pathogens spreading during the epidemic season 20212022 and the frequency of co-infection with SARS-CoV-2 and influenza. AIM: To assess the development of the influenza epidemic and frequency of cases of co-infection with respiratory pathogens in patients with acute respiratory viral infections between 2021 and 2022. MATERIALS AND METHODS: Traditional and hospital epidemiological surveillance methods for acute respiratory viral infections were used. RESULTS: The epidemic season of 20212022 was characterized by the early activity of the influenza A(H3N2) virus and the emergence and rapid spread of the omicron variant of SARS-CoV-2. The distribution of different respiratory pathogens during the epidemic season 20212022 was clearly traced: SARS-CoV-2 (18.8%) was predominant, followed by influenza viruses (10.6%) and pathogens of other acute respiratory viral infections (0.43.7%). With respect to influenza A (H3N2) and B viruses, the heterogeneity of their populations and drift variability in relation to vaccine strains were noted. DISCUSSION: The frequency of co-infection with various respiratory pathogens was low, i.e., it was no more than 0.1%according to traditional surveillance, and no more than 9.2% in the hospital surveillance. The rationale for updating the composition of influenza vaccines for the countries in the Northern Hemisphere for 20222023 season was identified. CONCLUSION: At present, early diagnosis of influenza is important given the availability of effective drugs with a direct mechanism of action for the prevention and treatment of this pathogen. Timely use of anti-influenza drugs will reduce the risks of a severe course, complications, and death, including co-infection with SARS-CoV-2.
- 1 June 2023
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 28 (2) , 67-77
Open AccessEpidemic season 2021–2022: Frequency of co-infection by respiratory viral pathogens
BACKGROUND: This study was conducted to determine the characteristics of various viral respiratory pathogens spreading during the epidemic season 20212022 and the frequency of co-infection with SARS-CoV-2 and influenza. AIM: To assess the development of the influenza epidemic and frequency of cases of co-infection with respiratory pathogens in patients with acute respiratory viral infections between 2021 and 2022. MATERIALS AND METHODS: Traditional and hospital epidemiological surveillance methods for acute respiratory viral infections were used. RESULTS: The epidemic season of 20212022 was characterized by the early activity of the influenza A(H3N2) virus and the emergence and rapid spread of the omicron variant of SARS-CoV-2. The distribution of different respiratory pathogens during the epidemic season 20212022 was clearly traced: SARS-CoV-2 (18.8%) was predominant, followed by influenza viruses (10.6%) and pathogens of other acute respiratory viral infections (0.43.7%). With respect to influenza A (H3N2) and B viruses, the heterogeneity of their populations and drift variability in relation to vaccine strains were noted. DISCUSSION: The frequency of co-infection with various respiratory pathogens was low, i.e., it was no more than 0.1%according to traditional surveillance, and no more than 9.2% in the hospital surveillance. The rationale for updating the composition of influenza vaccines for the countries in the Northern Hemisphere for 20222023 season was identified. CONCLUSION: At present, early diagnosis of influenza is important given the availability of effective drugs with a direct mechanism of action for the prevention and treatment of this pathogen. Timely use of anti-influenza drugs will reduce the risks of a severe course, complications, and death, including co-infection with SARS-CoV-2.
- Open Access
- 13 December 2022
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 27 (3) , 148-163
Predictive model of COVID-19 outcomes in patients with advanced HIV infection
BACKGROUND: No studies have examined the course and outcomes of coronavirus disease 2019 (COVID-19) in patients with advanced HIV infection, which prompted this analysis. AIM: To identify predictors of the adverse outcomes of COVID-19 in patients with HIV at the stage of secondary diseases to develop a predictive model of outcomes. This will help simplify the decision-making on the management of patients with COVID-19 and HIV infection at advanced stages. MATERIALS AND METHODS: This single-center study included 300 patients aged 18 years with HIV infection at advanced disease stage and moderate-to-severe COVID-19 requiring in-patient treatment. RESULTS: The mortality rate was 27.3% (95% CI, 22.7%32.4%). Factors reflecting respiratory failure, immunodeficiency, decreased levels of protein and albumin, and increased levels of urea became unfavorable. A predictive model of adverse outcomes of COVID-19 in patients with advanced HIV infection has been obtained. CONCLUSIONS: The proposed predictive model can help a practical healthcare doctor make a quick, informed decision on hospitalization of a patient in the intensive care unit and active therapeutic actions.
- 13 December 2022
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 27 (3) , 148-163
Open AccessPredictive model of COVID-19 outcomes in patients with advanced HIV infection
BACKGROUND: No studies have examined the course and outcomes of coronavirus disease 2019 (COVID-19) in patients with advanced HIV infection, which prompted this analysis. AIM: To identify predictors of the adverse outcomes of COVID-19 in patients with HIV at the stage of secondary diseases to develop a predictive model of outcomes. This will help simplify the decision-making on the management of patients with COVID-19 and HIV infection at advanced stages. MATERIALS AND METHODS: This single-center study included 300 patients aged 18 years with HIV infection at advanced disease stage and moderate-to-severe COVID-19 requiring in-patient treatment. RESULTS: The mortality rate was 27.3% (95% CI, 22.7%32.4%). Factors reflecting respiratory failure, immunodeficiency, decreased levels of protein and albumin, and increased levels of urea became unfavorable. A predictive model of adverse outcomes of COVID-19 in patients with advanced HIV infection has been obtained. CONCLUSIONS: The proposed predictive model can help a practical healthcare doctor make a quick, informed decision on hospitalization of a patient in the intensive care unit and active therapeutic actions.
- Open Access
- 13 September 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (4) , 16-26
Features of the Circulation of ARVI Pathogens During of Emergence and Widespread of SARS-CoV-2 in the 2018–2021
Relevance. The long-term leadership of ARVI pathogens determines their significance in the damage caused to both health and the economy of the country. Aim. To identify the features of the structure of ARVI during the emergence and widespread spread of SARS-CoV-2. Materials and methods. The article uses methods used in epidemiological surveillance of acute respiratory viral infections. Results and discussion. The results of the diagnostic available ARVI pathogens monitoring during epidemic seasons 2018-2021 are presented. The tendency of greater engagement of aged group 15 y.o. and older in epidemic process by morbidity and hospitalization due to SARI was shown. 49 818 nasal swabs from patients with influenza infection, 36 044 – with ARVI and 59 062 – with SARS-CoV-2 were tested. The top three in the structure of ARVI were INF, HEV-D and HRSV (in the 2018–2019 season); INF, SARS-CoV-2 and HEV-D (2019–2020); SARS-CoV-2, HEV-D and HPIV/HCoV (2020–2021). The activity of viral pathogens also differed: for HPIV, HAdV, HEV-D, HMPV, a decrease in activity was noted during the appearance of SARS-CoV-2 (2019–2020) and some of its growth in the following season; in relation to HRSV and INF - a decrease in activity during the last two seasons, and for INF – extremely low activity in the 2020-2021 season; the activity of seasonal HCoV even increased slightly. The data of genetic analyses of SARS-CoV-2 positive samples showed the heterogeneity of its population with a representative of variants (Alfa, Delta) as well as endemic for Russia and Moscow variants only. The recommended composition of influenza virus vaccines for use in the 2021–2022 northern hemisphere influenza season and in the 2022 southern hemisphere influenza season are presented due to their drift changeability. Conclusions. SARS-CoV-2 was influenced by the activity of ARVI pathogens with the almost complete displacement of influenza viruses from the circulation in the period 2020–2021.
- 13 September 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (4) , 16-26
Open AccessFeatures of the Circulation of ARVI Pathogens During of Emergence and Widespread of SARS-CoV-2 in the 2018–2021
Relevance. The long-term leadership of ARVI pathogens determines their significance in the damage caused to both health and the economy of the country. Aim. To identify the features of the structure of ARVI during the emergence and widespread spread of SARS-CoV-2. Materials and methods. The article uses methods used in epidemiological surveillance of acute respiratory viral infections. Results and discussion. The results of the diagnostic available ARVI pathogens monitoring during epidemic seasons 2018-2021 are presented. The tendency of greater engagement of aged group 15 y.o. and older in epidemic process by morbidity and hospitalization due to SARI was shown. 49 818 nasal swabs from patients with influenza infection, 36 044 – with ARVI and 59 062 – with SARS-CoV-2 were tested. The top three in the structure of ARVI were INF, HEV-D and HRSV (in the 2018–2019 season); INF, SARS-CoV-2 and HEV-D (2019–2020); SARS-CoV-2, HEV-D and HPIV/HCoV (2020–2021). The activity of viral pathogens also differed: for HPIV, HAdV, HEV-D, HMPV, a decrease in activity was noted during the appearance of SARS-CoV-2 (2019–2020) and some of its growth in the following season; in relation to HRSV and INF - a decrease in activity during the last two seasons, and for INF – extremely low activity in the 2020-2021 season; the activity of seasonal HCoV even increased slightly. The data of genetic analyses of SARS-CoV-2 positive samples showed the heterogeneity of its population with a representative of variants (Alfa, Delta) as well as endemic for Russia and Moscow variants only. The recommended composition of influenza virus vaccines for use in the 2021–2022 northern hemisphere influenza season and in the 2022 southern hemisphere influenza season are presented due to their drift changeability. Conclusions. SARS-CoV-2 was influenced by the activity of ARVI pathogens with the almost complete displacement of influenza viruses from the circulation in the period 2020–2021.
- 1 January 2021
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 10 (4)
West Nile fever on the territory of the Moscow agglomeration
Лихорадка Западного Нила на территории Московской агломерации
- 1 January 2021
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 10 (4)
West Nile fever on the territory of the Moscow agglomeration
Лихорадка Западного Нила на территории Московской агломерации
- Open Access
- 15 June 2020
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 25 (3) , 140-152
Trichinosis: outbreak description and brief literature review
Presented here is a description of trichinosis outbreak associated with bear meat consumption in the form of basturma and chips. The clinical, epidemiological, and laboratory characteristics of the disease course in observed three patients are given. In addition, a review of modern literature on the problem of trichinosis is presented, including issues of etiology, epidemiology, developmental cycle of trichinella, and features of disease clinical course, diagnosis, and treatment. Criteria to be looked at when trichinosis is suspected are also discussed.
- 15 June 2020
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 25 (3) , 140-152
Open AccessTrichinosis: outbreak description and brief literature review
Presented here is a description of trichinosis outbreak associated with bear meat consumption in the form of basturma and chips. The clinical, epidemiological, and laboratory characteristics of the disease course in observed three patients are given. In addition, a review of modern literature on the problem of trichinosis is presented, including issues of etiology, epidemiology, developmental cycle of trichinella, and features of disease clinical course, diagnosis, and treatment. Criteria to be looked at when trichinosis is suspected are also discussed.